Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 258

1.

Adjunctive simvastatin for treatment-resistant depression: study protocol of a 12-week randomised controlled trial.

Husain MI, Chaudhry IB, Khoso AB, Husain MO, Rahman RR, Hamirani MM, Hodsoll J, Carvalho AF, Husain N, Young AH.

BJPsych Open. 2019 Jan;5(1):e13. doi: 10.1192/bjo.2018.84.

2.

Associations between childhood maltreatment and inflammatory markers.

Palmos AB, Watson S, Hughes T, Finkelmeyer A, McAllister-Williams RH, Ferrier N, Anderson IM, Nair R, Young AH, Strawbridge R, Cleare AJ, Chung R, Frissa S, Goodwin L, Hotopf M, Hatch SL, Wang H, Collier DA, Thuret S, Breen G, Powell TR.

BJPsych Open. 2019 Jan;5(1):e3. doi: 10.1192/bjo.2018.80.

3.

Tamoxifen for bipolar disorder: Systematic review and meta-analysis.

Palacios J, Yildiz A, Young AH, Taylor MJ.

J Psychopharmacol. 2019 Feb;33(2):177-184. doi: 10.1177/0269881118822167. Epub 2019 Feb 11.

PMID:
30741085
4.

Brain activation during human defensive behaviour: A systematic review and preliminary meta-analysis.

Patrick F, Kempton MJ, Marwood L, Williams SCR, Young AH, Perkins AM.

Neurosci Biobehav Rev. 2019 Jan 3;98:71-84. doi: 10.1016/j.neubiorev.2018.12.028. [Epub ahead of print] Review.

PMID:
30611801
5.

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis - CORRIGENDUM.

Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F, Cleare AJ, Young AH.

Br J Psychiatry. 2018 Dec 19:1. doi: 10.1192/bjp.2018.291. [Epub ahead of print] No abstract available.

PMID:
30566398
6.

Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.

Jelen LA, King S, Horne CM, Lythgoe DJ, Young AH, Stone JM.

Eur Neuropsychopharmacol. 2019 Dec;29(2):222-234. doi: 10.1016/j.euroneuro.2018.12.005. Epub 2018 Dec 14.

PMID:
30558824
7.

Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.

Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6.

PMID:
30520709
8.

Psychiatry foretold.

Hidalgo-Mazzei D, Young AH.

Aust N Z J Psychiatry. 2018 Dec 4:4867418816821. doi: 10.1177/0004867418816821. [Epub ahead of print] No abstract available.

PMID:
30514099
9.

A new inner-city specialist programme reduces readmission rates in frequently admitted patients with bipolar disorder.

Macritchie K, Mantingh T, Hidalgo-Mazzei D, Bourne S, Borthwick E, Young AH.

BJPsych Bull. 2018 Nov 28:1-3. doi: 10.1192/bjb.2018.89. [Epub ahead of print]

10.

Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis.

Strawbridge R, Carter B, Marwood L, Bandelow B, Tsapekos D, Nikolova VL, Taylor R, Mantingh T, de Angel V, Patrick F, Cleare AJ, Young AH.

Br J Psychiatry. 2019 Jan;214(1):42-51. doi: 10.1192/bjp.2018.233. Epub 2018 Nov 20.

PMID:
30457075
11.

Revising Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project.

Parker G, Tavella G, Macqueen G, Berk M, Grunze H, Deckersbach T, Dunner DL, Sajatovic M, Amsterdam JD, Ketter TA, Yatham LN, Kessing LV, Bassett D, Zimmerman M, Fountoulakis KN, Duffy A, Alda M, Calkin C, Sharma V, Anand A, Singh MK, Hajek T, Boyce P, Frey BN, Castle DJ, Young AH, Vieta E, Rybakowski JK, Swartz HA, Schaffer A, Murray G, Bayes A, Lam RW, Bora E, Post RM, Ostacher MJ, Lafer B, Cleare AJ, Burdick KE, O'Donovan C, Ortiz A, Henry C, Kanba S, Rosenblat JD, Parikh SV, Bond DJ, Grunebaum MF, Frangou S, Goldberg JF, Orum M, Osser DN, Frye MA, McIntyre RS, Fagiolini A, Manicavasagar V, Carlson GA, Malhi GS.

Aust N Z J Psychiatry. 2018 Oct 31:4867418808382. doi: 10.1177/0004867418808382. [Epub ahead of print]

PMID:
30378461
12.

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder.

de Jong S, Diniz MJA, Saloma A, Gadelha A, Santoro ML, Ota VK, Noto C; Major Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, Curtis C, Newhouse SJ, Patel H, Hall LS, O Reilly PF, Belangero SI, Bressan RA, Breen G.

Commun Biol. 2018 Oct 8;1:163. doi: 10.1038/s42003-018-0155-y. eCollection 2018.

13.

Author's reply.

Young AH.

J Psychopharmacol. 2018 Oct;32(10):1150. doi: 10.1177/0269881118788823a. No abstract available.

PMID:
30293525
14.

Restrictions on drugs with medical value: Moving beyond stalemate.

Freeman TP, Mehta MA, Neill JC, Nutt DJ, Tunbridge EM, Young AH.

J Psychopharmacol. 2018 Oct;32(10):1053-1055. doi: 10.1177/0269881118798609. Epub 2018 Oct 2. No abstract available.

PMID:
30278146
15.

Prescreening clinical trial volunteers using an online personality questionnaire.

Patrick F, Young AH, Williams SC, Perkins AM.

Neuropsychiatr Dis Treat. 2018 Sep 5;14:2297-2303. doi: 10.2147/NDT.S169469. eCollection 2018.

16.

Growth Factor Proteins and Treatment-Resistant Depression: A Place on the Path to Precision.

Pisoni A, Strawbridge R, Hodsoll J, Powell TR, Breen G, Hatch S, Hotopf M, Young AH, Cleare AJ.

Front Psychiatry. 2018 Aug 23;9:386. doi: 10.3389/fpsyt.2018.00386. eCollection 2018.

17.

OpenSIMPLe: A real-world implementation feasibility study of a smartphone-based psychoeducation programme for bipolar disorder.

Hidalgo-Mazzei D, Reinares M, Mateu A, Nikolova VL, Bonnín CDM, Samalin L, García-Estela A, Pérez-Solá V, Young AH, Strejilevich S, Vieta E, Colom F.

J Affect Disord. 2018 Dec 1;241:436-445. doi: 10.1016/j.jad.2018.08.048. Epub 2018 Aug 14.

PMID:
30145515
18.

Ideology over evidence?

Jauhar S, Young AH.

BJPsych Bull. 2018 Jun;42(3):130-131. doi: 10.1192/bjb.2018.32. No abstract available.

19.
20.

Genomic Dissection of Bipolar Disorder and Schizophrenia, Including 28 Subphenotypes.

Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Electronic address: douglas.ruderfer@vanderbilt.edu; Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium.

Cell. 2018 Jun 14;173(7):1705-1715.e16. doi: 10.1016/j.cell.2018.05.046.

PMID:
29906448

Supplemental Content

Loading ...
Support Center